Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer’s disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.
Metrics to compare | NXL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNXLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.1x | −2.9x | −0.4x | |
PEG Ratio | −0.03 | 0.01 | 0.00 | |
Price/Book | 2.4x | 4.6x | 2.6x | |
Price / LTM Sales | 29.4x | 3.2x | 3.2x | |
Upside (Analyst Target) | - | 46.8% | 51.5% | |
Fair Value Upside | Unlock | 7.4% | 6.8% | Unlock |